miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths.
• MicroRNAs (miRNAs) play crucial roles in cancer development and immune regulation.
• The specific role of miR-142-5p in NSCLC immunity remains to be fully elucidated.

Purpose of the Study:

• To investigate the function of miR-142-5p in NSCLC immunity.
• To elucidate the underlying molecular mechanisms involving CD4+ T cells, PTEN, and PD-L1.
• To assess the potential of miR-142-5p as a therapeutic target in NSCLC.

Main Methods:

• Analysis of miR-142-5p expression and CD4+ T cell levels in NSCLC patients.
• In vitro experiments involving overexpression and downregulation of miR-142-5p in NSCLC cell lines.
• Assessment of protein expression levels of PTEN, PI3K, p-Akt, and PD-L1.
• Evaluation of the impact of miR-142-5p modulation on CD4+ T cell-mediated anti-cancer effects.

Main Results:

• miR-142-5p expression was upregulated, and CD4+ T cell levels were reduced in NSCLC patients.
• Overexpression of miR-142-5p inhibited CD4+ T cell anti-cancer activity, while downregulation enhanced it.
• miR-142-5p modulated PTEN, PI3K, p-Akt, and PD-L1 protein expression in vitro.
• Modulation of PD-L1 and PTEN affected CD4+ T cell-mediated anti-cancer effects in NSCLC.

Conclusions:

• miR-142-5p plays a significant role in regulating anti-tumor immunity in NSCLC.
• The mechanism involves the regulation of CD4+ T cell function through the PTEN/PD-L1 pathway.
• miR-142-5p represents a potential therapeutic target for enhancing anti-cancer immunity in NSCLC.